UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Exogenous Restoration of TUSC2 Expression Induces Responsiveness to Erlotinib in Wildtype Epidermal Growth Factor Receptor (EGFR) Lung Cancer Cells through Context Specific Pathways Resulting in Enhanced Therapeutic Efficacy

PloS one, 2015-06, Vol.10 (6), p.e0123967-e0123967

2015

Volltextzugriff (PDF)

Phase II Study of Preoperative Gefitinib in Clinical Stage I Non–Small-Cell Lung Cancer

Journal of clinical oncology, 2009-12, Vol.27 (36), p.6229-6236

2009

Volltextzugriff (PDF)

The Role of Intrapulmonary De Novo Lymphoid Tissue in Obliterative Bronchiolitis after Lung Transplantation

The Journal of immunology (1950), 2009-06, Vol.182 (11), p.7307-7316

2009

Volltextzugriff (PDF)

Selected Reaction Monitoring (SRM) Analysis of Epidermal Growth Factor Receptor (EGFR) in Formalin Fixed Tumor Tissue

Clinical proteomics, 2012-05, Vol.9 (1), p.5-5, Article 5

2012

Volltextzugriff (PDF)

P2-14-57 (B). 1L Pembrolizumab+Carbo+Taxane With / Without Maintenance Olaparib in Squamous NSCLC : KEYLYNK-008

Japanese Journal of Lung Cancer, 2020-10, Vol.60 (6), p.709-709

2020

Volltextzugriff (PDF)

ENP-8. KEYLYNK-012 : Pembrolizumab+CCRT Then Pembrolizumab±Olaparib vs CCRT Then Durvalumab in NSCLC

Japanese Journal of Lung Cancer, 2021-10, Vol.61 (6), p.557-557

2021

Volltextzugriff (PDF)

The right drugs at the right time for the right patient: the MD Anderson precision oncology decision support platform

Drug discovery today, 2015-12, Vol.20 (12), p.1433-1438

2015

Volltextzugriff (PDF)

Phase 3 study of pembrolizumab with concurrent chemoradiation therapy followed by pembrolizumab with or without olaparib versus concurrent chemoradiation therapy followed by durvalumab in unresectable, locally advanced, stage III non-small cell lung cancer: KEYLYNK-012

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.TPS8580-TPS8580

2021

Volltextzugriff (PDF)

Gene Therapy for Lung Cancer

Critical reviews in oncogenesis, 2016, Vol.21 (1-2), p.115-124

2016

Volltextzugriff (PDF)

Abstract CT030: Phase I dose escalation trial of pegzilarginase in patients with advanced solid tumors

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.CT030-CT030

2018

Volltextzugriff (PDF)

Phase 1 trial of pegzilarginase in patients (pts) with relapsed/refractory (R/R) AML or MDS refractory to hypomethylating agents (HMAs)

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.7031-7031

2018

Volltextzugriff (PDF)

Abstract 870: Synergistic antitumor activity of AKT inhibitor MK2206 and FUS1-nanoparticles in LKB1 mutant NSCLC

Cancer research (Chicago, Ill.), 2012-04, Vol.72 (8_Supplement), p.870-870

2012

Volltextzugriff (PDF)

Using Ontology Fingerprints to disambiguate gene name entities in the biomedical literature

Database : the journal of biological databases and curation, 2015, Vol.2015, p.bav034-bav034

2015

Volltextzugriff (PDF)

Abstract CT034: Results from phase 3 KEYLYNK-008: Pembrolizumab (pembro) with and without maintenance olaparib (ola) after first-line (1L) pembro plus chemotherapy (chemo) for metastatic squamous non-small-cell lung cancer (sqNSCLC)

Cancer research (Chicago, Ill.), 2024-04, Vol.84 (7_Supplement), p.CT034-CT034

2024

Volltextzugriff (PDF)

Abstract CT253: Results from KEYNOTE-B99: Phase 2 study of first-line (1L) pembrolizumab (pembro) plus investigational agents and chemotherapy (chemo) for extensive-stage small-cell lung cancer (ES-SCLC)

Cancer research (Chicago, Ill.), 2024-04, Vol.84 (7_Supplement), p.CT253-CT253

2024

Volltextzugriff (PDF)

Tissue Heterogeneity of EGFR Mutation in Lung Adenocarcinoma

Journal of thoracic oncology, 2008-05, Vol.3 (5), p.527-529

2008

Volltextzugriff (PDF)

Histopathological and immunohistochemical features associated with clinical response to neoadjuvant gefitinib therapy in early stage non-small cell lung cancer

Lung cancer (Amsterdam, Netherlands), 2012-05, Vol.76 (2), p.235-241

2012

Volltextzugriff (PDF)

Lung adenocarcinoma with Concurrent KRAS Mutation and ALK Rearrangement Responding to Crizotinib: Case Report

The International journal of biological markers, 2015-04, Vol.30 (2), p.254-257

2015

Volltextzugriff (PDF)

Peripheral lung nodules: fluoroscopically guided video-assisted thoracoscopic resection after computed tomography-guided localization using platinum microcoils

Annals of surgery, 2004-09, Vol.240 (3), p.481-489

2004

Volltextzugriff (PDF)

Clinical Forum: Breast cancer in young women in Mexico: unmet needs and clinical challenges

Revista de investigacion clinica, 2014-11, Vol.66 (6), p.547-558

2014

Volltextzugriff (PDF)

A window of opportunity study of potential tumor and soluble biomarkers of response to preoperative erlotinib in early stage non-small cell lung cancer

Oncotarget, 2016-05, Vol.7 (18), p.25632-25639

2016

Volltextzugriff (PDF)

Prevalence of incidental actionable germline mutations in 1,000 advanced cancer patients on a prospective somatic genomic profiling program

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.1510-1510

2015

Volltextzugriff (PDF)

Surgery for early non-small cell lung cancer with preoperative erlotinib (SELECT): A correlative biomarker study

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.7516-7516

2013

Volltextzugriff (PDF)

EGFR in Early Non-Small Cell Lung Cancer: Tyrosine Kinase Inhibition in a Neoadjuvant Trial

Lara-Guerra, Humberto

2011

Volltextzugriff (PDF)

Selected Reaction Monitoring in Formalin Fixed Tumor Tissue

Clinical proteomics, 2012-05, Vol.9

2012

Volltextzugriff (PDF)

1 – 25 von 32

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(27)
Mit Volltextzugriff
(27)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Humans
(11)
Science & Technology
(11)
Female
(10)
Life Sciences & Biomedicine
(10)
Lung Neoplasms - Genetics
(7)
Middle Aged
(7)
Animals
(6)
Carcinoma, Non-Small-Cell Lung - Genetics
(6)
Mutation
(6)
Oncology
(6)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(5)
Lung Neoplasms - Drug Therapy
(5)
Male
(5)
Antineoplastic Agents - Therapeutic Use
(4)
Tumors
(4)
Adult
(3)
Aged
(3)
Carcinoma, Non-Small-Cell Lung - Pathology
(3)
Epidermal Growth Factor
(3)
Lung Cancer
(3)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Exogenous Restoration of TUSC2 Expression Induces Responsiveness to Erlotinib in Wildtype Epidermal Growth Factor Receptor (EGFR) Lung Cancer Cells through Context Specific Pathways Resulting in Enhanced Therapeutic Efficacy

Phase II Study of Preoperative Gefitinib in Clinical Stage I Non–Small-Cell Lung Cancer

The Role of Intrapulmonary De Novo Lymphoid Tissue in Obliterative Bronchiolitis after Lung Transplantation

Selected Reaction Monitoring (SRM) Analysis of Epidermal Growth Factor Receptor (EGFR) in Formalin Fixed Tumor Tissue

P2-14-57 (B). 1L Pembrolizumab+Carbo+Taxane With / Without Maintenance Olaparib in Squamous NSCLC : KEYLYNK-008

ENP-8. KEYLYNK-012 : Pembrolizumab+CCRT Then Pembrolizumab±Olaparib vs CCRT Then Durvalumab in NSCLC

The right drugs at the right time for the right patient: the MD Anderson precision oncology decision support platform

Phase 3 study of pembrolizumab with concurrent chemoradiation therapy followed by pembrolizumab with or without olaparib versus concurrent chemoradiation therapy followed by durvalumab in unresectable, locally advanced, stage III non-small cell lung cancer: KEYLYNK-012

Gene Therapy for Lung Cancer

Abstract CT030: Phase I dose escalation trial of pegzilarginase in patients with advanced solid tumors

Phase 1 trial of pegzilarginase in patients (pts) with relapsed/refractory (R/R) AML or MDS refractory to hypomethylating agents (HMAs)

Abstract 870: Synergistic antitumor activity of AKT inhibitor MK2206 and FUS1-nanoparticles in LKB1 mutant NSCLC

Using Ontology Fingerprints to disambiguate gene name entities in the biomedical literature

Abstract CT034: Results from phase 3 KEYLYNK-008: Pembrolizumab (pembro) with and without maintenance olaparib (ola) after first-line (1L) pembro plus chemotherapy (chemo) for metastatic squamous non-small-cell lung cancer (sqNSCLC)

Abstract CT253: Results from KEYNOTE-B99: Phase 2 study of first-line (1L) pembrolizumab (pembro) plus investigational agents and chemotherapy (chemo) for extensive-stage small-cell lung cancer (ES-SCLC)

Tissue Heterogeneity of EGFR Mutation in Lung Adenocarcinoma

Histopathological and immunohistochemical features associated with clinical response to neoadjuvant gefitinib therapy in early stage non-small cell lung cancer

Lung adenocarcinoma with Concurrent KRAS Mutation and ALK Rearrangement Responding to Crizotinib: Case Report

Peripheral lung nodules: fluoroscopically guided video-assisted thoracoscopic resection after computed tomography-guided localization using platinum microcoils

Clinical Forum: Breast cancer in young women in Mexico: unmet needs and clinical challenges

A window of opportunity study of potential tumor and soluble biomarkers of response to preoperative erlotinib in early stage non-small cell lung cancer

Prevalence of incidental actionable germline mutations in 1,000 advanced cancer patients on a prospective somatic genomic profiling program

Surgery for early non-small cell lung cancer with preoperative erlotinib (SELECT): A correlative biomarker study

EGFR in Early Non-Small Cell Lung Cancer: Tyrosine Kinase Inhibition in a Neoadjuvant Trial

Selected Reaction Monitoring in Formalin Fixed Tumor Tissue

Suchergebnisse filtern